The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
DKK 2016 | Prolonging remission and survival in multiple myeloma
At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Christof Scheid, MD, PhD, from University of Cologne, Cologne, Germany, evaluates current and emerging approaches for managing patients with multiple myeloma, including drug sequencing and a clinical trial investigating lenalidomide, bortezomib, dexamethasone and elotuzumab as induction therapy for newly diagnosed patients.
